Related Experiment Video
Updated: May 31, 2025
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
The cost-effectiveness of vaccination against COVID-19 illness during the initial year of vaccination
Lisa A Prosser1, Janamarie Perroud2, Grace S Chung3
1Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, MI, USA; Susan B. Meister Child Health and Evaluation Research Center, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA.
Background:
Substantial investments by government programs and private health plans subsidized the costs of COVID-19 vaccine doses and vaccine administration. The objective of this study was to evaluate the cost-effectiveness of vaccination against COVID-19 illness during the initial year of COVID-19 vaccination (2021).
Methods:
Using a simulation model, we projected outcomes for hypothetical cohorts of US adults aged 18 and older, stratified by age and risk status for complications, comparing vaccination and no vaccination in the context of recommended concomitant prevention strategies (e.g., masking, social distancing). Vaccination against COVID-19 illness and complications used a pooled vaccination strategy for the 3 products available in 2021. Primary outcome measures included incremental cost-effectiveness ratio (ICER), projected costs, and projected quality-adjusted life years (QALYs). The model was parameterized using US epidemiologic, clinical, and cost data and the analysis used the healthcare and societal perspectives.
Results:
For vaccination against COVID-19 illness compared with no vaccination, vaccination yielded cost savings and QALY gains for all adult age and risk groups using the societal perspective. Using a healthcare sector perspective, ages 18-39 years required a net investment with ICERs ranging from $8400 to $15,000/QALY. Scenarios evaluating vaccine incentive programs mostly yielded ICERs <$100,000/QALY except for worker bonuses of $500 which yielded ICERs of $22,000 to $134,000/QALY. Results were most sensitive to costs of vaccination (dose cost, administration cost, travel and vaccination time costs) across uncertainty analyses.
Conclusion:
Investment in the 2021 vaccination program was attractive from an economic perspective even when using a very conservative approach to the analysis. Future vaccination programs in the US, with different associated cost structures, should be assessed to ensure ongoing value for COVID-19 vaccination.
Related Concept Videos
01:51Vaccinations
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:20Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...